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Cascade diagrams for depicting complex interventions
in randomised trials
Clarity about how trial interventions are delivered is important for researchers and those who might
want to use their results. A new graphical representation aims to help make complex interventions
clearer
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Manymedical interventions—particularly non-pharmacological
ones—are complex, consisting of multiple interacting
components targeted at different organisational levels.1 2
Published descriptions of complex interventions often do not
contain enough detail to enable their replication.2-5 Reports of
behaviour change interventions should include descriptions of
setting, mode, intensity, and duration, and characteristics of the
participants.6 Graphical methods, such as that showing the
relative timing of assessments and intervention components,7
may improve clarity of reporting. However, these approaches
do not reveal the connections between the different “actors” in
a complex intervention.8Different audiences may want different
things from a description of an intervention, but visualising
relationships between actors can clarify crucial features such
as the fidelity with which the intervention is passed down a
chain of actors9 and possible routes of contamination between
treatment arms. Herewe describe a new graphical approach—the
cascade diagram—that highlights these potential problems.
Hierarchical interventions
Figure 1a⇓ is a schematic illustration of a hierarchically
delivered intervention. At the top is a health professional or
primary investigator who trains several health professionals at
the next level down to deliver the intervention to a common
standard. Each of these second level professionals then delivers
the intervention to patients at the third level. In this example
we suppose that patients are treated in groups: thus each patient
receives input from a health professional (the arrow coming
down from the second level) and also from the other patients
in their group (drawn as a circulating arrow at the lowest level),
and these inputs combine or interact to produce a health benefit.
In fig 1b⇓ we have uncluttered the diagram by separating out
the information showing the relationships between actors at
different levels. The circulating arrow allows us to show the
contact between patients and the level at which it occurs without
having to depict more than one patient. We can no longer see
how many actors there are at different levels, or the range of
their characteristics: these things are important to report, but
current guidelines recommend that they be included in the
CONSORT flowchart and in text or tables.6 10 What we are left
with is a diagram showing the flow from the source of the
intervention, at the top, down to the patient who receives it, at
the bottom. This simple idea is the basis for the cascade diagram.
Figure 2a⇓ shows the graphical elements that make up a cascade
diagram: actors (rectangular boxes), hierarchical levels not
represented by an actor (rounded boxes), and intervention
components (arrows with labels, indexed in a separate key). As
an example we illustrate in fig 2b a parenting intervention for
preterm infants described by Johnson and colleagues.11 In this
study the trial manager trained research nurses in the delivery
of the active intervention, and each nurse delivered the
intervention to mothers of babies in neonatal intensive care
units. Mothers then cared for their infants, whose cognitive
outcomes were assessed at 2 years.
As a general rule, our diagrams exclude actors who provide
only routine care, with no influence from any experimental
intervention. In fig 2 we have excluded intensive care unit staff,
who were not trained in the intervention. We have, however,
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included the neonatal intensive care units in the hierarchy
because it allows us to show the extent of communication
between mothers taking part in the study. The exchange of
information between mothers is shown as a circulating arrow
extending back as far (horizontally) as the level of the intensive
care unit and no further, the assumption being that contact
between mothers extends only as far as those attending the same
unit, and not, for example, to those seen by the same research
nurse.
The diagonal arrangement of actors denotes the cascade of an
intervention through a hierarchy. Different actors at the same
level, who do not stand in a hierarchical or sequential
relationship to each other, can be shown one under the other,
or side by side, depending on what works best in the diagram.
We use singular rather than plural nouns in our actor boxes
(“research nurse” rather than “research nurses”) to avoid
ambiguity about who delivers the intervention. A box may
contain more than one person if they interact jointly with the
actor at the next level—for example, we might write “general
practitioner and practice nurse” or simply “practice staff” if
these were the people a patient had contact with—but wewould
recommend writing, for example, “midwife” rather than
“midwives” unless each participant was seen by a whole team
of midwives.
Trials
So far we have discussed how to illustrate the delivery of an
active intervention, but we would like our diagrams to go further
and show the different treatment arms in a trial. In fig 3⇓ we
illustrate our suggested approach using a variety of simple two
arm trial designs.
Figure 3a⇓ shows the simplest kind of trial, with participants
randomised individually. We indicate randomisation with a
shaded banner running behind the two randomised groups. As
before, we do not include actors who provide only routine care.
In this example, the control participant is isolated graphically:
there is no link through which he or she can receive the active
intervention—that is, no possible route for contamination.
Figure 3b⇓ shows how an individually randomised design can
lead to contamination in something like a general practice
setting, where patients attending the same practice share
information about the care they receive. Practice is shown as
an organisational marker, with no actors at this level involved
in delivering the intervention. Patient to patient contact within
a practice is indicated by the circulating arrow, which shows
information circulating within the bounds defined by a practice.
Because there are control and intervention participants at the
same practice, this circulating flow provides a route through
which the active intervention can pass to, or contaminate, control
participants.
Figure 3c⇓ shows how a cluster randomised trial avoids
contamination in this situation.12 If we assume that the flow of
information between participants does not extend between
clusters—in this case between patients at different general
practices—then the circulating flow among control participants
is effectively isolated from the flow among intervention
participants. The diagram shows that there is no route through
which the active intervention can pass to control participants.
Finally, fig 3d⇓ shows a cluster randomised trial in which the
intervention is aimed at cluster (practice) level, its effects then
being cascaded down to individual participants. Again,
contamination is avoided by randomising in clusters.
More complex interventions
We developed cascade diagrams after considering how to
describe real life trials of complex interventions. Here we
illustrate one example, the Older People’s Exercise Intervention
in Residential and Nursing Accommodation (OPERA) trial,13
whichwas a trial of an exercise programme to reduce depression.
We consulted in depth on the graphical representation of
OPERA with its chief investigators as well as those conducting
a process evaluation of the trial, to produce summaries that they
found helpful. The results are shown in the web appendix, where
we present the cascade diagram, the diagram proposed by Perera
and colleagues (the PaT plot),14 and the CONSORT flowchart
for OPERA, to show how these approaches complement each
other (the numbers in the CONSORT flowchart have been left
blank, as these were unpublished at the time we developed the
supplement).
The CONSORT flowchart, which should always be included
in a trial report,10 summarises the flow of individuals through a
trial, whereas the cascade diagram is a model of the flow of
interventions. The PaT plot describes the timing of different
intervention components, while the cascade diagram shows the
relationships between the actors delivering them. Detailed
information about intervention components is included in the
key to the cascade diagram, which also acts as the key to the
PaT plot. Between them, the cascade diagram, PaT plot, key,
and CONSORT flowchart form a complete description of a trial
of a multicomponent, multilevel intervention such as OPERA.
Even for a complex intervention, we suggest that the cascade
diagram be kept as simple as possible. Actors who only provide
routine care can be left out unless that care is contaminated by
an experimental intervention, though we will always need to
show, at the lowest level, the individual participant or unit of
analysis. Different boxes referring to the same type of actor are
needed when different actors are randomised into different arms;
when the same actor fulfils more than one role in a trial,
however, there should just be one box for that actor. The
appearance of more than one of the same kind of actor in the
diagram, unless at the randomisation level, alerts us to situations
where actors are separated into non-randomised groups—for
example, midwives at a maternity unit being divided
non-randomly into those who treat intervention mothers and
those who treat controls—a situation that should usually be
avoided.
Discussion
We have introduced a simple but powerful graphical approach
to describe the delivery of a complex intervention in a trial. The
method focuses on aspects that are not well addressed by
existing approaches to reporting.
A recent, evidence based assessment of the key dimensions in
describing complex interventions distinguished between the
timing of intervention components, for which a diagrammatic
approach has already been successfully introduced,7 and other
features— including “structure and architecture” and dependence
on healthcare professionals—which our cascade diagrams
attempt to depict.15 Cascade diagrams may be useful after a
study as a tool facilitating implementation or evidence synthesis,
and before a study to encourage researchers to reflect on their
design.4 8 Managers considering how to adopt a published
intervention can use the diagram to compare their institutional
context with the one in which the intervention was evaluated.15
At the design stage researchers can show design choices and
identify methodological problems such as contamination or
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non-randomised groups—part of the crucial “modelling” phase
in the development and evaluation of a complex intervention.16
Contamination arising through contact between individuals at
one level of a hierarchy is not always a bad thing: at the level
of individual participants it can help to reinforce an intervention;
at an intermediate health professional level it can help to
standardise it.
Cascade diagrams are particularly useful for describing
interventions delivered in a hierarchical context and for those
whose complexity arises from a truly complex system, not just
a complicated one.17 For example, the diagram shows how,
rather than flowing straight down a cascading sequence of actors,
an intervention can be reinforced or altered by circulating
currents within hierarchical levels. The box representing each
actor in the diagram is a “black box”: arrows enter and leave
but may combine inside the box in non-linear ways.
We have limited the range of graphical elements in the diagrams
to make them as intuitive as possible, but researchers may want
to play with them further—for example, different arrow styles
could distinguish intervention components according to whether
the standardisation being proposed was by function or form.15 18
Graphical methods in general continue to interest researchers.18 19
Graphs and figures can be included as online extras in a journal
article even when editorial policy limits the number of figures
in the print version. Cascade diagrams have some features in
common with Unified Modelling Language (UML) sequence
diagrams, which are also beginning to find applications in health
services research.20 A Microsoft Word toolkit for producing
cascade diagrams is available from the authors.
Commentators agree that much needs to be done to improve
the reporting of trials of complex interventions.2-6 The more
people are able to understand what other researchers have done,
the more likely they are to reproduce, cite, and discuss this work.
We offer our diagrammatic approach as one new tool to aid in
this complex task.
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Figures
Fig 1 (a) Illustration of a hierarchically delivered intervention: a health professional or primary investigator at the top level
trains several health professionals to deliver the intervention to a common standard; each second level professional then
delivers the intervention to patients in a group setting. Circulating arrows show the intervention circulating within a group
(the second level professionals are trained separately and independently, so there is no circulating arrow at this level). (b)
Abstraction of the first diagram showing the relationships between actors at different levels
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Fig 2 (a) Graphical elements making up the cascade diagram. (b) Cascade diagram for the parent-baby interaction programme
(PBIP), a parenting intervention for very preterm infants in neonatal intensive care units (NICU)11
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Fig 3 Cascade diagrams for various designs of randomised controlled trial: (a) a trial with individuals randomised to two
arms; (b) an individually randomised trial in a general practice setting, showing contamination; (c) the same trial cluster
randomised by practice; (d) a cluster randomised trial of an intervention delivered by general practice staff
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